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ole of Diminished Renal
unction in Cardiovascular Mortality
arker or Pathogenetic Factor?
obert W. Schrier, MD
enver, Colorado
The interactions between the heart and the kidney recently have been the focus of intense
interest because of epidemiological evidence indicating that even mild deterioration of renal
function is an important risk factor for poor outcome in patients with congestive heart failure,
myocardial infarction, and cardiovascular surgery. Kidney function deterioration may be a
consequence of cardiac and baroreceptor dysfunction or may be primarily caused by intrinsic
kidney disease. This review provides a comprehensive analysis of the role of the kidney not
only as a marker but also as a pathogenic factor in cardiorenal syndromes, whether primary
heart or primary kidney disease or both are the initiators of the subsequent pathophysiological
events. (J Am Coll Cardiol 2006;47:1–8) © 2006 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.067Foundation
r
d
b
m
s
r
F
d
c
l
d
h
o
C
c
a
r
o
i
i
s
C
i
m
a
b
c
f
e
o
d
I
u
tild or moderate decreases in renal function have been
hown to correlate with significant morbidity and mortality
n patients with asymptomatic and symptomatic congestive
eart failure (CHF) (1–3), those with myocardial infarction
4), and those undergoing cardiovascular surgery (5). Also,
atients with mild chronic renal insufficiency are known to
ave a significant increase in cardiovascular morbidity and
ortality (6,7). However, the mechanisms whereby even
ild deterioration of renal function has been found to be a
ajor cardiovascular risk factor are not known. One possi-
ility is that cardiac pump failure may secondarily lead to
iminished renal function, and thus early renal failure may
nly be a marker of impaired cardiac function. Alternatively,
ven mild or moderate renal dysfunction may also be a
athogenetic factor in causing the progression of functional
ardiac deterioration. The potential mechanisms whereby
ven mild renal dysfunction could be an important contrib-
tor to the progression of cardiac disease and cardiovascular
ortality are the focus of this review.
IDNEY FUNCTION AS A RISK FACTOR FOR CHF
major role of the kidney is the regulation of extracellular
uid (ECF) volume (8). Minor abnormalities in kidney
unction can impair this capacity to maintain ECF volume
ithin the normal range. In this regard, there are consid-
rable data that indicate that the initiating event in the
athogenesis of essential hypertension is renal sodium
etention, which occurs in the presence of apparent normal
idney function (9). In this regard, the hallmark of CHF is
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nd Hypertension, Denver, Colorado. Studies performed by the author and cited in
his review were supported by grants funded by the NIH PO1 DK 19928 and NIH
R4000051.L
Manuscript received March 31, 2005; revised manuscript received July 7, 2005,
ccepted July 18, 2005.enal sodium and water retention. Thus, the use of loop
iuretics in CHF patients with dyspnea and shortness of
reath is standard therapy. In patients with CHF, diuretics
ay induce a natriuresis, decrease ECF volume, and provide
ymptomatic relief; however, cardiac function generally
emains stable or decreases depending on the patient’s
rank-Starling curve. If the diuretic-induced natriuresis
ecreases cardiac pre-load to an extent that diminishes
ardiac index, the blood urea nitrogen and serum creatinine
evels may increase and cause the clinician to discontinue or
ecrease the dose of the loop diuretic (10). There are,
owever, several mechanisms whereby persistent volume
verload may lead to progression of heart failure (HF).
ardiac dilation in CHF. Expansion of ECF can increase
ardiac pre-load and lead to cardiac dilation, which can have
deleterious effect on cardiac function. The myocardial
emodeling that occurs with cardiac dilation can increase
xygen demand and create a situation of relative myocardial
schemia. Cardiac dilation can also cause functional mitral
nsufficiency, which may contribute to pulmonary hyperten-
ion and impair left and right ventricular function. In early
HF, ventricular dilation is association with an increase
n brain natriuretic peptide (BNP), which may facilitate
aintenance of sodium balance and suppress the renin-
ngiotensin-aldosterone system. Exogenous BNP has also
een shown to decrease cardiac pre-load (11), diminish
ardiac fibrosis (12), and enhance the diuretic effect of
urosemide (13). In patients with more advanced CHF, the
ffect of natriuretic peptides may be blunted (14) as a result
f decreased renal perfusion pressure and diminished so-
ium delivery to the distal nephron site of BNP action.
ncreased left ventricular (LV) mass index in CHF. Vol-
me overload and increased cardiac pre-load can increase
ransmural myocardial pressure and increase LV mass index.
eft ventricular hypertrophy is a major cardiovascular risk
f
d
c
t
i
t
A
i
i
f
r
a
t
r
r
a
(
r
r
a
b
r
c
i
a
s
p
i
c
a
o
i
r
a
a
s
c
C
c
p
i
A
i
k
p
d
m
m
a
s
e
s
a
c
h
b
i
c
r
r
p
s
d
e
a
e
S
s
e
a
i
t
A
d
t
u
r
f
l
c
m
o
e
F
f
a
2 Schrier JACC Vol. 47, No. 1, 2006
Diminished Renal Function in Cardiovascular Mortality January 3, 2006:1–8actor with increased mortality relating to systolic and/or
iastolic dysfunction, arrhythmias, and sudden death. Be-
ause the hypertrophied myocardium has a relative reduc-
ion in capillary density, an increase in ischemic events,
ncluding angina and infarction, also occur with LV hyper-
rophy (15).
ttenuation of atrial-renal reflexes in CHF. An increase
n atrial pressure, as occurs with CHF, has been shown to
nitiate several reflexes that have a beneficial effect on renal
unction. An increase in left atrial pressure suppresses the
elease of the antidiuretic hormone arginine vasopressin,
nd leads to a water diuresis that is abolished by vagotomy,
he so-called Henry-Gauer Reflex (16). Another normal
esponse to an increase in left atrial pressure is a decrease in
enal sympathetic tone (17). An increase in atrial pressure
lso has been shown to increase atrial natriuretic peptide
18). These atrial-renal reflexes, which normally enhance
enal sodium excretion, are impaired during CHF because
enal sodium and water retention occur despite elevated
trial pressures. Chronic CHF in the dog has been shown to
e associated with a blunting of the atrial-renal sympathetic
eflex (19). Although the elevated plasma vasopressin con-
entrations have been shown to be suppressed with an
ncrease in atrial pressure in HF, the plasma levels of this
ntidiuretic hormone still remained increased and no diure-
is occurred (20). Moreover, in contrast to normal subjects,
lasma levels of atrial natriuretic hormone were found not to
ncrease further during a saline load in patients with dilated
ardiopathy and mild HF, and the natriuretic response was
lso blunted (21). There is also evidence that the attenuation
f these reflexes on the low pressure side of the circulation
s not only attributable to a blunting of the atrial-renal
eflexes, but also may in part be caused by counteracting
rterial baroreceptor-renal reflexes. There is evidence of
utonomic dysfunction and blunted arterial baroreceptor
ensitivity in CHF (22). This is associated with increased
irculating catecholamines and renal sympathetic activity in
HF, and in fact plasma norepinephrine concentrations
orrelate with mortality (23). There is also evidence for
arasympathetic withdrawal in CHF in addition to the
ncrease in sympathetic drive (24).
ctivation of the renin-angiotensin-aldosterone system
n CHF. The renin-angiotensin-aldosterone system is
nown to be activated in patients with CHF, and in fact
lasma renin activity also has been shown to correlate
irectly with mortality. Angiotensin II is known to cause
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CHF  congestive heart failure
ECF  extracellular fluid
GFR  glomerular filtration rate
HF  heart failure
LV  left ventricularyocardial remodeling (25), and aldosterone may increase
fl
tyocardial fibrosis and necrosis in the heart (26). Moreover,
ngiotensin II is known to be a potent stimulator of the
ympathetic nervous system (27). There is also experimental
vidence for angiotensin generation in the central nervous
ystem during cardiac failure, as evidenced by an increase in
ngiotensin concentration in the cerebrospinal fluid. In-
reased angiotensin and decreased nitric oxide in the brain
ave been implicated as mediators of the blunting of
aroreceptor sensitivity in experimental CHF (28). The
ncrease in renal sympathetic tone secondary to this barore-
eptor perturbation would be expected to cause sodium
etention by several mechanisms (Fig. 1). Angiotensin and
enal nerve stimulation both activate receptors on the
roximal tubule epithelium, which enhances sodium reab-
orption (29,30). Furthermore, the resultant decreased so-
ium delivery to the distal nephron impairs the normal
scape mechanism from the sodium-retaining effect of
ldosterone. The renal vasoconstriction of the glomerular
fferent arteriole by angiotensin II in CHF also alters net
tarling forces in the peritubular capillary (decreased hydro-
tatic and increased oncotic pressure) in a direction to
nhance sodium reabsorption (31). Thus, angiotensin and
lpha-adrenergic stimulation increase sodium reabsorption
n the proximal tubule by a direct effect on the proximal
ubule epithelium and secondarily by renal vasoconstriction.
ldosterone increases sodium reabsorption in the collecting
uct. Competitive inhibitors of the mineralocorticoid recep-
ors in the distal nephron, i.e., spironolactone (32), can be
sed in HF to reverse the aldosterone-mediated sodium
etention. These mineralocorticoid antagonists are the pre-
erred diuretics in cirrhosis, and there are important simi-
arities in the mechanisms of sodium retention in CHF and
irrhosis (33). There is, however, the danger of hyperkale-
ia in CHF patients treated with mineralocorticoid antag-
nists, particularly in the presence of angiotensin converting
nzyme inhibitors, angiotensin receptor blockers, and/or
igure 1. Decreased baroreceptor sensitivity in patients with chronic heart
ailure can worsen cardiac function by increasing renin-angiotensin-
ldosterone system (RAAS) and sympathetic activity, enhancing proximal
uid reabsorption, impairing aldosterone escape, and blunting the response
o natriuretic peptides. Na  sodium.
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January 3, 2006:1–8 Diminished Renal Function in Cardiovascular Mortalityeta-blockers (34). The potassium-losing effect of loop and
hiazide diuretics and a low potassium diet may, however,
ounterbalance the potassium-retaining effect of mineralo-
orticoid antagonists and thereby avoid the potential side
ffect of hyperkalemia. When mineralocorticoid antagonists
re used to treat sodium retention in patients with CHF, the
oses of spironolactone need in general to be higher than
he 25 to 50 mg used for cardiac protection in the Random-
zed Aldactone Evaluation Study (35) to compete with the
levated endogenous concentrations of aldosterone. Because
ldosterone has also been shown to cause renal fibrosis,
ineralocorticoid antagonists may also exert a protective
ffect on the kidney in HF patients (36).
The juxtaglomerular apparatus of the kidney is a major
ediator of the activation of the renin-angiotensin-
ldosterone system. Specifically, renal beta-adrenergic stim-
lation (37) and decreased sodium chloride delivery to the
acula densa (38), which are expected events with CHF,
re known to stimulate the renin-angiotensin-aldosterone
ystem. Moreover, with edema, the interstitial and venous
ressure of the kidney may increase, perhaps in part because
f the rigid renal capsule, and stimulate the renin-
ngiotensin-aldosterone system (31).
Thus, in CHF, activation of the renin-angiotensin-
ldosterone system may cause progression of the cardiac
ysfunction by: 1) direct myocardial effects of angiotensin
nd aldosterone causing cardiac remodeling and fibrosis,
nd 2) increasing proximal sodium reabsorption and impair-
ng aldosterone escape, thereby perpetuating volume over-
oad with the potential for cardiac dilation, LV hypertrophy,
nd blunting beneficial atrial-renal reflexes. Moreover, the
esultant volume overload in HF patients is most frequently
reated with loop diuretics, which block sodium chloride
ransport at the macula densa, with resultant further acti-
ation of the renin-angiotensin-aldosterone system (39).
Angiotensin converting enzyme inhibitors and angioten-
in receptor blockers have been shown to improve mortality
n patients with symptomatic (3) and asymptomatic (2) HF.
evertheless, the predominant vasoconstrictor effect of
ngiotensin on the efferent arteriole is important in main-
aining glomerular hydrostatic pressure and thus the
lomerular filtration rate. Therefore, inhibition of the
ngiotensin-converting enzyme or angiotensin receptors in
he patient with CHF may worsen renal function (40) and
hereby perpetuate the sodium retention and volume over-
oad, with the aforementioned deleterious consequences.
he HF patients most likely susceptible to this adverse
ffect of angiotensin II inhibition are those who have
lready-elevated serum creatinine concentrations and are
eceiving diuretics.
There is another renal aspect of the treatment of CHF
hat is worthy of discussion. Cardiac afterload reduction
ith angiotensin inhibition or vasodilators may enhance
ardiac index (41) and thereby improve renal function,
ncluding the capacity to maintain sodium and water bal-
nce. However, overly aggressive arterial vasodilation will aause relative arterial underfilling, and thus renal perfusion
ressure, in spite of an increase in cardiac index. In this
egard, a decrease in renal perfusion pressure has been
hown to increase tubular sodium reabsorption (42) and
hus potentially can worsen the deleterious effects of volume
verload in the patient with CHF. Excessive arterial vaso-
ilation to decrease cardiac afterload will further activate the
enin-angiotensin-aldosterone and sympathetic systems.
The mechanisms that have been discussed thus far,
hereby perturbations in kidney function may contribute to
rogression of cardiac disease by chronic volume overload
nd activation of the renin-angiotensin and sympathetic
ervous systems are of a functional nature and are therefore
otentially reversible. It must be acknowledged, however,
hat similar cardiac consequences of volume overload can
ccur as a consequence of intrinsic renal disease. For
xample, in CHF patients with diabetes or essential hyper-
ension, renal microvascular disease may occur and lead to
odium and water retention and the cardiac consequences of
olume overload.
OLE OF DIURETICS IN CHF:
OSITIVE AND NEGATIVE ASPECTS
he use of loop diuretics in CHF may worsen renal function
43). Because even mild renal dysfunction has been associ-
ted with increased cardiovascular mortality, the positive
nd negative aspects of the use of diuretics in patients with
HF must be considered. In symptomatic HF patients
here is little question about the positive role of diuretics in
reating congestion of the lung and pulmonary symptoms of
yspnea and shortness of breath. Moreover, with severe
ulmonary edema, hypoxia, hypercapnia, and metabolic
cidosis may occur and depress myocardial function (44). In
his setting, treatment with diuretics may not only benefit
he pulmonary symptoms, but by correcting these acid-base
isorders, cardiac function may improve.
On the other hand, as noted above, the use of diuretics in
ome cardiac failure patients may lead to deterioration of
enal function. Thus, the question emerges whether these
atients with CHF should be maintained in a volume
verload state to maximize their cardiac index on the
rank-Starling curve and preserve renal function. Support
or such a conservative treatment approach is generally
dopted in those CHF patients whose blood urea nitrogen
nd serum creatinine levels increase during diuretic treat-
ent. However, as discussed previously, if diminished renal
unction with increased cardiac filling pressure and ventric-
lar dilation because of chronic volume overload is not just
marker of poor prognosis but rather is also a contributor to
rogression of cardiac dysfunction, a therapeutic dilemma
requently emerges with respect to diuretic therapy. Fluid
emoval by ultrafiltration may be recommended in this
etting, in which the use of loop diuretics is associated with
eterioration of renal function (45). Although a descending
rm of the Frank-Starling curve has not been identified,
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Diminished Renal Function in Cardiovascular Mortality January 3, 2006:1–8ome CHF patients with renal dysfunction, i.e., increased
lood urea nitrogen and serum creatinine levels, actually
mprove their renal function after diuretic-induced weight
oss. The mechanism for this improvement may relate to the
eversal of one or more of the factors discussed earlier,
hereby chronic volume overload may cause deterioration of
ardiac function (Fig. 2).
Fluid removal by ultrafiltration in patients with severe
HF may have theoretical advantages over loop diuretics.
irst, relative or absolute diuretic resistance may occur with
dvanced cardiac failure (46), even when a combination of
arge doses of loop diuretics and a thiazide diuretic are used.
oreover, the use of large doses of these diuretics may have
eleterious effects on cardiac function by their potassium-
nd magnesium-losing properties. Second, the fluid re-
oved by ultrafiltration is isotonic with plasma, whereas the
iuresis with loop diuretics is virtually always hypotonic to
lasma. Therefore, for the same volume of fluid removal,
ltrafiltration removes more sodium than diuretic therapy
nd also avoids electrolyte disturbances. Because sodium
nd its anion are the major determinants of ECF volume,
ltrafiltration decreases ECF volume more than a compa-
able volume of diuretic-induced fluid loss. Moreover, as
iscussed earlier, loop diuretics block sodium chloride trans-
ort at the macula densa and thus activate the renin-
ngiotensin-aldosterone system (39) with its accompanying
otential deleterious effects in the patients with CHF.
owever, because the role of fluid mobilization from the
nterstitium to vascular compartment is limited to 12 to 14
l/min in HF (47), an over-aggressive rate of fluid removal
y ultrafiltration may also activate the renin-angiotensin-
ldosterone system. Nevertheless, for loop diuretics to be
ffective, they will always inhibit sodium chloride transport
n the thick ascending limb of the loop of Henle including
he macula densa, and thereby consistently stimulate the
enin-angiotensin-aldosterone system. Stimulation of the
igure 2. Mechanisms in congestive heart failure whereby negative sodiumr
nd water balance by loop diuretics or ultrafiltration therapy may improve
yocardial function.enin-angiotensin-aldosterone system as a consequence of
oop diuretic use has been shown to be a major factor in the
ccurrence of diuretic resistance (46). Recently, in a random-
zed study of a tachycardia-induced porcine model of HF,
urosemide administration shortened the time to LV dys-
unction and elevated serum aldosterone levels as compared
ith placebo independent of detectable differences in car-
iac pre-load (48).
Despite the theoretical advantages of fluid removal by
ltrafiltration over loop diuretics in the patient with ad-
anced CHF and the reported beneficial effects in non-
andomized studies of small numbers of patients (47), a
rospective randomized study will be needed to establish an
dvantage of ultrafiltration over diuretic-induced therapy in
HF. Moreover, ultrafiltration is an invasive procedure and
s more costly than diuretic treatment. Nevertheless, if
ltrafiltration in selective patients is shown in future studies
o decrease hospitalizations for HF (approximately one
illion/year in the U.S.), the treatment may be shown to be
ost effective in some settings.
Recently, phase III studies with a vasopressin receptor
ntagonist in HF patients have shown weight loss associated
ith electrolyte-free water excretion without changes in
lood pressure, renal function, or neurohumoral hormones
49). However, it must be remembered that with electrolyte-
ree water excretion after equilibration, only one-third of the
olume loss will be from extracellular fluid, with the
emaining loss from the intracellular component.
In addition to the antagonism of the V2 vasopressin
ntagonist on the renal collecting duct with the resultant
ater diuresis, there are theoretical reasons why antagonism
f the V1a vasopressin receptor on cardiomyocytes and
ascular smooth muscle could also be of therapeutic benefit
n cardiac failure (Fig. 3).
Figure 4 shows how renal sodium retention can feed back
nd diminish plasma aldosterone and return cardiac index to
ear normal values. Thus, observing heart failure patients at
nly one snap shot in time, rather than observing the entire
ontinuum can be misleading. Other circumstances where
eart failure may be associated with renal dysfunction but a
ormal cardiac output include patients with diastolic dys-
unction, impaired baroreceptor activity, and/or renal pa-
enchymal disease (i.e., renal-cardiac syndrome).
HRONIC KIDNEY DISEASE AS A RISK
ACTOR FOR CARDIOVASCULAR OUTCOMES
tudies in high-risk cardiovascular populations and patients
ith cardiovascular disease have consistently shown that the
evel of kidney function is an independent risk factor for
ardiovascular mortality (6,7). Chronic kidney disease has been
efined as an estimated glomerular filtration rate of 60
l/min/1.73 m2. At this level of kidney function a number of
ardiovascular risk factors may occur, including volume expan-
ion secondary to sodium retention, hypertension, and insulin-
esistance with impaired glucose tolerance. Chronic kidney
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January 3, 2006:1–8 Diminished Renal Function in Cardiovascular Mortalityisease has also been associated with increased oxidative stress,
vidence of inflammation (e.g., increased c-reactive protein)
50,51), phosphate retention with medial vascular calcification
52), increased parathyroid hormone concentrations with myo-
ardial calcification and dysfunction (53), and anemia and LV
ypertrophy (54), all of which could increase cardiovascular
isease (55) (Fig. 5). Increased plasma homocysteine, fibrino-
en, and uric acid are other cardiovascular risk factors that
ccur with chronic kidney disease (56). Albuminuria has clearly
een shown to be not only a risk factor for progression of
hronic kidney disease but also a risk factor for cardiovascular
ortality (57). Although some of these factors may only be
arkers of cardiovascular disease, it is clear that some are
athogenetic factors for cardiovascular outcomes. The Chronic
enal Insufficiency Cohort (CRIC) study should provide
nsight into the temporal relationship between these renal
actors and the cardiovascular complications (58).
In a recent analysis of four community-based studies of
2,634 subjects without a history of cardiovascular disease,
igure 3. Pathways whereby vasopressin stimulation of V2 and V1a
eceptors can contribute to events that worsen cardiac function.
igure 4. Myocardial injury can lead to sodium and water retention, which
an suppress the renin-angiotensin-aldosterone systems (RAAS) and
eturn cardiac index to a normal range. The dashed lines indicate the
athways of these feedback mechanisms. To exclude myocardial injurym
hen these feedback mechanisms have normalized the RAAS and cardiac
ndex would be a mistake.hronic kidney disease was shown to be a risk factor for the
rimary composite outcome of myocardial infarction, fatal
oronary artery disease, stroke, and diabetes (7). However,
n a sub-group analysis of the black population, chronic
idney disease was a greater risk factor for the primary
omposite cardiovascular end point than in the general
opulation. The black population at baseline also had a
istory of more diabetes and hypertension (7).
In a recent study of elderly patients with HF and LV
ysfunction, treatment with angiotensin converting enzyme
nhibitors significantly decreased the risk of death independent
f gender, age, race, or serum creatinine level (59). However,
he inhibitors were underprescribed, and an elevation of serum
reatinine level was the most significant predictor of failure to
rescribe this proven effective treatment.
HRONIC KIDNEY DISEASE AS
RISK FACTOR FOR OUTCOMES
FTER AN ACUTE MYOCARDIAL INFARCTION
here are several studies in which subjects with chronic
idney disease were found on follow-up to be associated
ith increased mortality after a myocardial infarction
60,61). This finding has been observed not only in elderly
ubjects after an acute myocardial infarction (62) but also in
more general population after a heart attack (63). As
escribed above, there are several factors with chronic
idney disease that could be pathogenetic factors and/or
arkers of cardiovascular outcome after an acute myocardial
nfarction. In a recent study of 14,527 patients with acute
igure 5. Multiple pathways whereby chronic renal parenchymal disease
ay increase cardiovascular morbidity and mortality by causing hyperten-
ion, atherosclerosis, and/or myocardial dysfunction. GFR  glomerular
ltration rate.yocardial infarction complicated by clinical or radiological
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Diminished Renal Function in Cardiovascular Mortality January 3, 2006:1–8igns of HF, LV dysfunction, or both, the risk of cardio-
ascular death increased with declining estimated glomeru-
ar filtration rate (GFR) beginning at a value 81 ml/min/
.73 m2 (64). In an accompanying editorial, Hostetter (65)
mphasizes the importance of calculating GFR, e.g., the
odification of Diet in Renal Disease (MDRD) formula
66) rather than using serum creatinine in such studies. This
s because of the non-linear relationship between serum
reatinine concentration and GFR, as well as the influence
f age, gender, and race.
MALL INCREASES IN SERUM CREATININE
S A CARDIOVASCULAR RISK FACTOR FOR
UTCOMES AFTER CARDIOVASCULAR SURGERY
cute renal failure in patients undergoing cardiac surgery
as been identified as the strongest risk factor for death, and
he mortality may approach 80% (67). Recently, however, it
as been reported that even minimal increases in serum
reatinine (0.5 mg/dl) within 48 h after cardiothoracic
urgery in 3,381 patients with a baseline serum creatinine
evel 1.3 mg/dl was associated with increased 30-day
ortality (hazard ratio, 7.09%) independent of the other
ariables, including the need for renal replacement therapy
5). This result is supportive of previous studies, which have
hown that small increases in serum creatinine level after
ardiac surgery are associated with increased non-renal
omplications and a poor prognosis (68,69). One explana-
ion for this relationship is that a small increase in serum
reatinine concentration after cardiothoracic surgery may be
sensitive marker of diffuse hypoperfusion throughout the
ody.
Even a small increase in serum creatinine concentration
fter cardiothoracic surgery may, however, be a contributing
actor to increased complications and mortality. For exam-
le, as serum creatinine doubles, renal function decreases by
0% (e.g., an increase in serum creatinine from 0.8 to 1.6
g/dl equates to a decrease in glomerular filtration rate
rom 100 to 50 ml/min) and the renal capacity to excrete
dministered fluid is impaired. With fluid overload and
ypoxia, mechanical ventilation may be instituted. It is well
stablished that the longer the period of ventilatory support,
he higher the mortality from pulmonary infection, oxygen
oxicity, barotrauma, and ultimately acute respiratory dis-
ress syndrome (70). Excessive fluid administration and
ore prolonged need for ventilatory support could be the
eason why a 0.3 mg/dl decrease in serum creatinine
oncentration (i.e., 1.67 to 1.11 mg/dl; p  0.001) within
8 h after cardiothoracic surgery was also shown to be a risk
actor for 30-day mortality (5).
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